Volume 18, Number 4—April 2012
Dispatch
De Novo Daptomycin-Nonsusceptible Enterococcal Infections
Theodoros Kelesidis
, Romney Humphries, Daniel Z. Uslan, and David Pegues
, Romney Humphries, Daniel Z. Uslan, and David PeguesTable 2
Antimicrobial susceptibilities of DNSE isolates from 9 patients to antimicrobial drugs with activity against Enterococcus spp., Los Angeles, California, USA, 2007–2011*
| Patient no. | Enterococcus species | MIC, μg/mL |
Synergy test |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAP† | VAN | AMP | DOX | NIT | LZD | Q-D | TGC | CIP | GEN | STR | |||
| 1 | E. faecium | ND | >32 (R) | >64 (R) | <1 (S) | 128 (R) | 2 (S) | <0.5 (S) | <0.25 (S) | >4 (R) | S | S | |
| 2 | E. faecium | ND | >32 (R) | >64 (R) | 8 (I) | 64 (I) | 2 (S) | <0.5 (S) | <0.25 (S) | >4 (R) | R | S | |
| 3 | E. faecium | ND | 2 (S) | >64 (R) | 16 (R) | 32 (S) | 1 (S) | <0.5 (S) | <0.25 (S) | >4 (R) | R | R | |
| 4 | E. faecalis | 4 | 1 (S) | <2 (S) | 16 (R) | <16 (S) | 2 (S) | 4 (R) | <0.25 (S) | 1 (S) | S | S | |
| 5 | E. faecalis | 12 | 2 (S) | <2 (S) | 8 (I) | <16 (S) | 2 (S) | 4 (R) | <0.25 (S) | 1 (S) | S | S | |
| 6 | E. faecium | 8 | >32 (R) | >64 (R) | 8 (I) | 32 (S) | 1 (S) | 1(S) | <0.25 (S) | >4 (R) | S | S | |
| 7 | E. gallinarum | 4 | <0.5 (S) | <2 (S) | <1(S) | 32 (S) | 1 (S) | 1(S) | <0.25 (S) | <0.5 (S) | S | S | |
| 8 | E. faecium | 8 | >32 (R) | >64 (R) | 4 (S) | 64 (I) | 2 (S) | <0.5 (S) | <0.25 (S) | >4 (R) | R | S | |
| 9 | E. faecium | ND | >32 (R) | >64 (R) | 4 (S) | 64 (I) | 1 (S) | 1 (S) | <0.25 (S) | >4 (R) | R | S | |
*DNSE, daptomycin-nonsusceptible enterococci; DAP, daptomycin; VAN, vancomycin; AMP, ampicillin; DOX, doxycycline; NIT, nitrofurantoin; LZD, linezolid; Q-D, quinupristin/dalfopristin; TGC, tigecycline; CIP, ciprofloxacin; GEN, gentamicin; STR, streptomycin; NS, nonsusceptible; ND, not done; R, resistant; S, sensitive.
†By Etest.
